A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
- Study Title
- A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age
- Teva Identifier
- TV48125-CNS-30083
- ClinicalTrials.gov Identifier
- NCT04458857
- Study Status
- Completed
- Trial Condition(s)
- Migraine
- Interventions
- Drug: Fremanezumab | Drug: Placebo
- EudraCT Number
- 2019-002055-42
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Child
- Age Range
- 6 Years to 17 Years
- Trial Duration
- July 15, 2020 - March 13, 2024
- Phase
- Phase 3